Asarinin inhibits immunological rejection via the Toll-like receptor-myeloid differentiation factor 88 signaling pathway in vitro
Transplant Immunology · 2023
DOI: 10.1016/j.trim.2023.101949 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Immunology, 2023. Verfasst von Lili Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Affiliated Longhua People's Hospital, Southern Medical University (Longhua People's Hospital), Shenzhen, Guangdong 518109, …. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, Toll-Like Receptor 4. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Foundation for Innovative Research Groups of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Asarinin has been found to prolong allograft survival and inhibit post-transplant immune rejection via the Toll-like receptor (TLR) signaling pathway. However, the underlying mechanism is not completely understood. Therefore, elucidating the possible pathophysiological role of asarinin in the TLR signaling pathway is essential. Here, dendritic cells were isolated from Sprague-Dawley® rats and cultured with splenocytes from Wistar rats treated with asarinin, lipopolysaccharide (LPS), and/or dimethyl sulfoxide. mRNA expression of TLR-2, TLR-4, myeloid differentiation factor 88 (MyD88), and nuclear factor kB (NF-kB) was determined using real-time polymerase chain reaction. Interleukin (IL)-6 and IL-12 levels were examined using an enzyme-linked immunosorbent assay. LPS resulted in an increase in the expression of TLR-2 rather than TLR-4 and MyD88. Furthermore, it inhibited the secretion of IL-6 and IL-12. MyD88 can be silenced after lentiviral transduction, and LPS can activate MyD88, whereas asarinin can inhibit this kind of activation. The effect of LPS and asarinin on TLR-4 could only be achieved when MyD88 was not silenced by lentivirus transduction. Therefore, asarinin might suppress TLR-4-mediated activation via the MyD88-dependent pathway. Overall, asarinin has a pre-application effect in inhibiting graft rejection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Affiliated Longhua People's Hospital, Southern Medical University (Longhua People's Hospital), Shenzhen, Guangdong 518109, PR China.
- Department of Cardiology, Affiliated Longhua People's Hospital, Southern Medical University (Longhua People's Hospital), Shenzhen, Guangdong 518109, PR China. Electronic address: drsunyanxia@126.com.
Förderung
- National Natural Science Foundation of China
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
Zitieren
APA
Zhang, L., Sun, Y., Yang, Z., & Xia, P. (2023). Asarinin inhibits immunological rejection via the Toll-like receptor-myeloid differentiation factor 88 signaling pathway in vitro. Transplant Immunology. https://doi.org/10.1016/j.trim.2023.101949
Vancouver
Zhang L, Sun Y, Yang Z, Xia P. Asarinin inhibits immunological rejection via the Toll-like receptor-myeloid differentiation factor 88 signaling pathway in vitro. Transplant Immunology. 2023. doi:10.1016/j.trim.2023.101949
BibTeX
@article{Zhang2023,
author = {Zhang, Lili and Sun, Yanxia and Yang, Zhen and Xia, Ping},
title = {Asarinin inhibits immunological rejection via the Toll-like receptor-myeloid differentiation factor 88 signaling pathway in vitro},
journal = {Transplant Immunology},
year = {2023},
doi = {10.1016/j.trim.2023.101949}
}
EUVIMED